Area of research
Pulmonary and Respiratory Medicine · Otorhinolaryngology
Research interest
Research interests include Renal cell carcinoma treatment, Head and Neck Cancer Studies, Bladder and Urothelial Cancer Treatments, and Cancer Immunotherapy and Biomarkers.
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02)
Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial